| 08.04.21 | J&J’s intravenous Uptravi approved by FDA; Boehringer inks deal to boost bioavailability

Laden...

3 jaren geleden

Html
Tekst

Aptar targets China with injectable takeover To view this email as a web page, click here

Webinar: Use of PBPK Modeling for Predicting and Optimizing Controlled Release Dosage Forms

Join this webinar to hear experts share methods that can help evaluate whether a molecule is suitable for controlled release applications. Watch Now.

Today's Rundown

FDA approves intravenous version of J&J's Uptravi to prevent treatment interruptions Boehringer taps Nanoform to boost solubility and bioavailability Aptar inks deal to target Chinese injectable drug delivery field Fresh from $225M IPO, atai founds nose-to-brain delivery startup Ipsen puts down $20M in $1B deal with Exicure for rare neuro disorders

Featured Story

FDA approves intravenous version of J&J's Uptravi to prevent treatment interruptions

By Nick Paul Taylor

The FDA has approved an injectable version of Johnson & Johnson’s pulmonary arterial hypertension drug Uptravi. J&J developed the formulation to allow patients to continue to receive treatment if they are temporarily unable to take the oral version of the drug.

Webinar: Accelerate late-phase drug development with continuous manufacturing

Wednesday, August 25, 2021 | 11am ET / 8am PT

Continuous manufacturing enables late-phase development by ensuring quality assurance and reducing API usage. Attend this webinar to learn how to create a strategy that reduces total cost of ownership. Register Now.

Boehringer taps Nanoform to boost solubility and bioavailability

By Nick Paul Taylor

Boehringer Ingelheim has struck a deal to apply Nanoform's nanoparticle technology to its preclinical pipeline prospects. The master services agreement positions the partners to work to improve the solubility and bioavailability of drug candidates in development at Boehringer.

Aptar inks deal to target Chinese injectable drug delivery field

By Nick Paul Taylor

Aptar has struck a deal to buy an 80% stake in Chinese injectable drug delivery player Weihai Hengyu Medical Products. The acquisition gives Aptar a chance to access the major market even if China tries to limit its reliance on imports from overseas.

Fresh from $225M IPO, atai founds nose-to-brain delivery startup

By Nick Paul Taylor

Atai Life Sciences has created a startup to develop a nose-to-brain delivery system for the treatment of mental health disorders. The startup, InnarisBio, has secured exclusive rights to a sol-gel nasal drug delivery platform in certain fields.

Ipsen puts down $20M in $1B deal with Exicure for rare neuro disorders

By Kyle LaHucik

Ipsen is digging deeper into neuroscience, with a $20 million upfront payment to Exicure in a discovery deal for up to two preclinical assets in Huntington's disease and Angelman syndrome. The agreement is back loaded with up to $1 billion in fees and focuses on two rare genetic disorders.